Navigation Links
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Date:8/21/2007

o target novel therapies for melanoma."

"I am pleased that the European Association of Dermato-Oncology (EADO) will be the lead international cooperative group for AGENDA," said Dr. Claus Garbe, Professor of Dermatology and Head of the Division of Dermatooncology, Department of Dermatology, University Medical Center, Tubingen, Germany. "The use of LDH to pre-select individuals who are disproportionately likely to benefit represents an important innovation for patient treatment."

"The Genasense/dacarbazine trial represents our highest treatment priority for patients with advanced melanoma," said Dr. Sanjiv Agarwala, Chief of Medical Oncology, St. Luke's Hospital and Health Network, Allentown, PA. "With our center now actively enrolling patients, we look forward to rapidly confirming the exciting results previously obtained in individuals with low- normal LDH."

About Genasense in Advanced Melanoma

Genasense, Genta's lead anticancer drug, is a novel targeted therapy that blocks the production of Bcl-2, a protein that appears to be a fundamental cause of cancer treatment resistance. By knocking down Bcl-2, Genasense may enhance the effectiveness of chemotherapy in patients with advanced melanoma. Genasense in melanoma has Orphan Drug designations in Australia and the U.S., along with Fast Track designation in the U.S.

In its initial Phase 3 trial, Genta performed the largest randomized controlled trial that has ever been conducted in patients with advanced melanoma. In that trial, 771 patients were randomly assigned to receive chemotherapy with DTIC alone or in combination with Genasense. A scientific article that describes efficacy and safety results from this study can be accessed at: http://www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1.

In that trial, patients were also prospectively stratified according to blood levels LDH. Further analysi
'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 17, ... (CTMC), and Integrated Clinical Trial Services, LLC (ICTS), ... for clinical trials announce that they have formed ... Services (i-CTMS). i-CTMS will provide a broad range ... biotechnology and medical device companies. i-CTMS ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/vt6973/mems_gyroscopes ) ... Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... a lot of progress in the past few ... accepted in high-reliability environments, and are even starting ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... Ikaria Holdings, Inc. today announced that it has been ... by the New Jersey Business & Industry Association (NJBIA), ... Ikaria earned the award based on criteria including ... creation of new jobs. , "We are delighted that ...
... 21 PharmaNet Development Group, Inc., a leading provider ... and medical device companies, today announced its participation at ... place at the World Trade Center in Rotterdam, The ... the conference, top management will discuss some of the ...
Cached Medicine Technology:Ikaria Receives Award for Excellence by New Jersey Business & Industry Association 2PharmaNet Development Group Management Participates in the 8th Annual Partnerships in Clinical Trials Conference in Rotterdam 2
(Date:12/17/2014)... 2014 Dr. Myo Nwe is the co-author ... of the Future” and co-founder of the Ace Medical Weight ... Nwe takes a broad look at the industry of weight ... scientific scrutiny. On film and in television shows, however, she ... the social aspects and played for basic laughs, which she ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 A group ... Center for Longevity, today, in reaction to a recent statement ... science of brain training and derogated the efficacy of all ... they agreed with the parts of the center’s statement critical ... believed the center had also overstated its case, in a ...
(Date:12/17/2014)... 17, 2014 Project Veritas is releasing ... videos of MIT economist and Obamacare architect Jonathan Gruber ... O’Keefe conducted the interview, which is being distributed on ... was intentional mislabeling in the Affordable Care Act in ... A two-hundred-and-fifty billion dollar per year tax grab. , ...
(Date:12/17/2014)... Dec. 16, 2014 (HealthDay News) -- Poor students get more ... a new study finds. But, the opposite is true ... having fruits and vegetables at school may give a healthy ... But, no matter what the family income level, students all ... the study found. The study was published recently in ...
(Date:12/17/2014)... Kathleen Doheny HealthDay Reporter ... loss is rampant in America, and work commitment is a ... No. 1 sleep killer," said Dr. Mathias Basner, an assistant ... of Pennsylvania Perelman School of Medicine. A time-use survey ... that work is the main activity exchanged for sleep. Short ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3
... may soon recommed patients who have undergone bowel surgery to ... found by Santa Barbara Cottage Hospital researchers that chewing gum ... This may in turn result in early discharge from the ... in the latest issue of Archives of Surgery journal. ...
... been a spurt of fungal infections in contact lens wearers ... against the seven reported last month. //This takes the overall ... suffered corneal infections and the Singapore National Eye Centre (SNEC) ... used Bausch and Lomb's (B&L) ReNu with MoistureLoc solution and ...
... Ramdev signed agreements with the Jharkhand government to set up ... plants.// ,The memorandums of understanding were signed in the ... ,Announcing government aid of Rs.10 million for the planned hospital, ... a herbal state that can benefit the common people of ...
... bizarre to you readers but if new research is to be ... // ,This revelation comes from American scientists who found that ... is by way of an increase the number of nerve connections ... ,The Yale University is credited with the study and ...
... of anabolic steroids, more specifically anabolic androgen steroid (AAS) ... sebaceous glands. Sebaceous glands present in the skin // ... of the body surface. ,Anabolic steroids are ... to treat unwanted weight loss in patients with HIV. ...
... of destruction caused by the Indian Ocean tsunami, the Katrina ... tsunami was responsible for the annihilation of 300,000 lives with ... tsunami arrived, it appeared as if the tourists were tsunami’s ... perhaps the only ones to sport a video camera at ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: